27 May 2014 14:26
27 May 2014 Venn Life Sciences Holdings Plc
("Venn" or the "Company")
Director's Dealing
Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces that David Evans, a director, has today purchased 210,000 ordinary shares of 0.1 pence each in the Company at a price of 20.5 pence per share.
David Evans now holds 289,033 ordinary shares of 0.1 pence each, representing 1.03 per cent. of the Company's issued share capital.
Enquiries:
| |
Venn Life Sciences Holdings Plc | |
Tony Richardson, Chief Executive Officer | Tel: +353 154 99 341 |
Zeus Capital Limited (Nominated Adviser and Broker) | |
Ross Andrews/Andrew Jones (Corporate Finance) | Tel: 0161 831 1512 |
Dominic Wilson (Institutional Sales)
| Tel: 020 7533 7727 |
Walbrook PR Ltd
Paul McManus | Tel: 020 7933 8787 or venn@walbrookpr.com Mob: 07980 541 893 |
Lianne Cawthorne | Mob: 07584 391 303 |